Eliem Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Co. is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver therapeutics for patients with these disorders. Co.'s two clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide prodrug for the treatment of diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica. The ELYM average annual return since 2021 is shown above.
The Average Annual Return on the ELYM average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ELYM average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ELYM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|